Brief: Belite Bio Announces Pricing Of $30 mln Underwritten Public Offering Of ADS And Warrants
Brief: Belite Bio Announces Proposed Underwritten Public Offering Of American Depositary Shares And Warrants
Brief: Belite Bio Files For Mixed Shelf Of Up To $300 Mln - SEC Filing
Brief: Belite Bio Files For Stock Shelf Offering Of Up To $300 Mln American Depositary Shares
Brief: Belite Bio Inc Files For Offering Of Up To $300 Mln American Depositary Shares
Brief: Belite Bio Presents 18-Month Interim Data From A 24-Month Phase 2 Study Of Tinlarebant
U.S. STOCKS ON THE MOVE-Grindr, Utilities, StoneCo, Carvana
Belite Bio up on finalizing late-stage eye drug study design
Brief: Belite Bio Finalizes Phase 3 Clinical Trial Plans For Advanced Dry AMD Treatment With Tinlarebant (LBS-008)
Belite Bio gains on China nod for lead drug trial
Brief: Belite Bio Receives Approval Of LBS-008 Phase 3 Clinical Trial In China
Belite Bio rises on starting enrolment for eye disease drug
Brief: Belite Bio Initiates Pivotal Phase 3 Clinical Trial Of Lbs-008 In Stargardt Disease In U.S.
Brief: Belite Bio Submits IND Application To FDA For Approval
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:54 PM
Brief: Belite Bio Presented Interim Results Of LBSs-008 Phase 1B/2 Study In Adolescent STGD1 At Arvo Annual Meeting 2022
- Belite Bio up on 'fast track' tag for eye disease drug
Brief: Belite Bio Receives FDA Fast Track Designation For Lbs-008
NASDAQ RESUMED AT 11:48 AM